Neutralizing antibodies against Plasmodium falciparum associated with successful cure after drug therapy

• Main Authors: Goh Y.S., Peng K., Chia W.N., Siau A., Chotivanich K., Gruner A.-C., Preiser P., Mayxay M., Pukrittayakamee S., Sriprawat K., Nosten F., White N.J., Renia L.
• Other Authors: DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
• Format: Article
• Published: 2019
• Subjects: artemether plus benflumetol; artesunate; azithromycin; EBA181 antibody; EXP1 antibody; GLURP antibody; MSP3 antibody; neutralizing antibody; parasite antigen; RAMA antibody; SEA antibody; unclassified drug; antimalarial agent; antiserum; artemether; artemisinin derivative; benflumetol; EBA-181 protein, Plasmodium falciparum; ethanolamine derivative; fluorene derivative; glutamate-rich protein, Plasmodium; merozoite surface protein 3, Plasmodium; protozoal protein; protozoon antibody; QF116 antigen, Plasmodium falciparum; adult; antibody response; antibody specificity; Article; clinical article; erythrocyte; human; human cell; malaria falciparum; merozoite; molecular library; nonhuman; parasite clearance; parasite isolation; Plasmodium falciparum; species invasion; acute disease; adolescent; biosynthesis; blood; cohort analysis; drug effects; female; genetics; growth, development and aging; humoral immunity; immunology; Malaria, Falciparum; male; parasitology; recurrent disease; treatment outcome; Acute Disease; Adolescent; Adult; Antibodies, Neutralizing; Antibodies, Protozoan; Antibody Specificity; Antigens, Protozoan; Antimalarials; Artemisinins; Azithromycin; Cohort Studies; Erythrocytes; Ethanolamines; Female; Fluorenes; Humans; Immune Sera; Immunity, Humoral; Male; Protozoan Proteins; Recurrence; Treatment Outcome
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/161566
• Institution: National University of Singapore

10.1371/journal.pone.0159347